Frederic Grabowski: Difference between revisions

Revision as of 08:50, 13 September 2023

B.Sc., Ph.D. student

Contact

e-mail at ippt.pan.pl: fgrabows
tel.: +48 22 8261280 ext. 450
room: 310

Institute of Fundamental Technological Research
Polish Academy of Sciences
Pawińskiego 5B, 02-106 Warsaw, Poland

Publications

Antagonism between viral infection and innate immunity at the single-cell level
Grabowski F, Kochańczyk M, Korwek Z, Czerkies M, Prus W, Lipniacki T.
PLOS Pathogens 19(9):e1011597 (2023)
PubMed CrossRef | bioRxiv Code Data

Predictive power of non-identifiable models
Grabowski F, Nałęcz-Jawecki P, Lipniacki T
Scientific Reports 13:11143 (2023)
CrossRef | bioRxiv Code

The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days can be explained by immune evasion
Grabowski F, Kochańczyk M, Lipniacki T.
Viruses 14(2):294 (2022)
PubMed CrossRef | medRxiv PDF Correspondence

SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and acquires concerning mutations
Grabowski F, Preibisch G, Giziński S, Kochańczyk M, Lipniacki T
Viruses 13(3):392 (2021)
PubMed CrossRef | medRxiv PDF SuppInfo-ZIP Correspondence

Super-spreading events initiated the exponential growth phase of COVID-19 with R₀ higher than initially estimated
Kochańczyk M, Grabowski F, Lipniacki T
Royal Society Open Science 7:200786 (2020)
PubMed CrossRef | PDF SuppInfo-PDF Correspondence

Dynamics of COVID-19 pandemic at constant and time-dependent contact rates
Kochańczyk M, Grabowski F, Lipniacki T
Mathematical Modelling of Natural Phenomena 15:28 (2020)
CrossRef | PDF SuppCode

Asymptotic safety and conformal standard model
Grabowski F, Kwapisz JH, Meissner KA
Physical Review D 99(11):115029 (2019)
CrossRef arXiv

Limits to the rate of information transmission through the MAPK pathway
Grabowski F, Czyż P, Kochańczyk M, Lipniacki T
Journal of the Royal Society Interface 16(152):20180792 (2019)
PubMed CrossRef | PDF SuppCode

@@ Line 12: / Line 12: @@
 <br /><br />
 ===Publications===
-* '''Antagonism between viral infection and innate immunity at the single-cell level'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Kochańczyk&nbsp;M</span>, <span class="pmbm">Korwek&nbsp;Z</span>, <span class="pmbm">Czerkies&nbsp;M</span>, <span class="pmbm">Prus&nbsp;W</span>, <span class="pmbm">Lipniacki&nbsp;T</span>.<br/>''PLOS Pathogens'' <u>19</u>(9):e1011597 (2023)<br/>[https://doi.org/10.1371/journal.ppat.1011597 CrossRef] [https://doi.org/10.1101/2022.11.18.517110 bioRxiv] [https://github.com/grfrederic/visavis Code] [https://doi.org/10.5281/zenodo.7428925 Data]
+* '''Antagonism between viral infection and innate immunity at the single-cell level'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Kochańczyk&nbsp;M</span>, <span class="pmbm">Korwek&nbsp;Z</span>, <span class="pmbm">Czerkies&nbsp;M</span>, <span class="pmbm">Prus&nbsp;W</span>, <span class="pmbm">Lipniacki&nbsp;T</span>.<br/>''PLOS Pathogens'' <u>19</u>(9):e1011597 (2023)<br/>[https://pubmed.ncbi.nlm.nih.gov/37669278 PubMed] [https://doi.org/10.1371/journal.ppat.1011597 CrossRef] | [https://doi.org/10.1101/2022.11.18.517110 bioRxiv] [https://github.com/grfrederic/visavis Code] [https://doi.org/10.5281/zenodo.7428925 Data]
-* '''Predictive power of non-identifiable models'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Nałęcz-Jawecki&nbsp;P</span>, <span class="pmbm">Lipniacki&nbsp;T</span><br/>''Scientific&nbsp;Reports'' <u>13</u>:11143 (2023)<br/>[https://doi.org/10.1038/s41598-023-37939-8 CrossRef] [https://doi.org/10.1101/2023.04.07.536025 bioRxiv] [https://github.com/grfrederic/identifiability Code]
+* '''Predictive power of non-identifiable models'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Nałęcz-Jawecki&nbsp;P</span>, <span class="pmbm">Lipniacki&nbsp;T</span><br/>''Scientific&nbsp;Reports'' <u>13</u>:11143 (2023)<br/>[https://doi.org/10.1038/s41598-023-37939-8 CrossRef] | [https://doi.org/10.1101/2023.04.07.536025 bioRxiv] [https://github.com/grfrederic/identifiability Code]
-* '''The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days&nbsp;can&nbsp;be&nbsp;explained by immune evasion'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Kochańczyk&nbsp;M</span>, <span class="pmbm">Lipniacki&nbsp;T</span>.<br/>''Viruses'' <u>14</u>(2):294 (2022)<br/>[https://pubmed.ncbi.nlm.nih.gov/35215887 PubMed] [https://doi.org/10.3390/v14020294 CrossRef] [https://dx.doi.org/10.1101/2021.12.08.21267494 medRxiv] | [https://www.mdpi.com/1999-4915/14/2/294/pdf PDF] [https://susy.mdpi.com/user/review/displayFile/23340271/tDGR6nk0?file=author-coverletter&report=16624478 Correspondence]
+* '''The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days&nbsp;can&nbsp;be&nbsp;explained by immune evasion'''<br/><span class="pmbm">Grabowski&nbsp;F</span>, <span class="pmbm">Kochańczyk&nbsp;M</span>, <span class="pmbm">Lipniacki&nbsp;T</span>.<br/>''Viruses'' <u>14</u>(2):294 (2022)<br/>[https://pubmed.ncbi.nlm.nih.gov/35215887 PubMed] [https://doi.org/10.3390/v14020294 CrossRef] | [https://dx.doi.org/10.1101/2021.12.08.21267494 medRxiv]  [https://www.mdpi.com/1999-4915/14/2/294/pdf PDF] [https://susy.mdpi.com/user/review/displayFile/23340271/tDGR6nk0?file=author-coverletter&report=16624478 Correspondence]
-* '''SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and&nbsp;acquires concerning mutations'''<br/><span class="author">Grabowski&nbsp;F</span>, <span class="author">Preibisch&nbsp;G</span>, <span class="author">Giziński&nbsp;S</span>, <span class="author">Kochańczyk&nbsp;M</span>, <span class="author">Lipniacki&nbsp;T</span><br/>''Viruses'' <u>13</u>(3):392 (2021)<br/>[https://pubmed.ncbi.nlm.nih.gov/33804556 PubMed] [https://doi.org/10.3390/v13030392 CrossRef] [https://doi.org/10.1101/2020.12.28.20248906 medRxiv] | [https://www.mdpi.com/1999-4915/13/3/392/pdf PDF] [https://www.mdpi.com/1999-4915/13/3/392/s1 SuppInfo-ZIP] [https://www.mdpi.com/1999-4915/13/3/392/review_report Correspondence]
+* '''SARS-CoV-2 Variant of Concern 202012/01 has about twofold replicative advantage and&nbsp;acquires concerning mutations'''<br/><span class="author">Grabowski&nbsp;F</span>, <span class="author">Preibisch&nbsp;G</span>, <span class="author">Giziński&nbsp;S</span>, <span class="author">Kochańczyk&nbsp;M</span>, <span class="author">Lipniacki&nbsp;T</span><br/>''Viruses'' <u>13</u>(3):392 (2021)<br/>[https://pubmed.ncbi.nlm.nih.gov/33804556 PubMed] [https://doi.org/10.3390/v13030392 CrossRef] | [https://doi.org/10.1101/2020.12.28.20248906 medRxiv]  [https://www.mdpi.com/1999-4915/13/3/392/pdf PDF] [https://www.mdpi.com/1999-4915/13/3/392/s1 SuppInfo-ZIP] [https://www.mdpi.com/1999-4915/13/3/392/review_report Correspondence]
 * '''Super-spreading events initiated the exponential growth phase of COVID-19 with <i>R</i><sub>0</sub> higher&nbsp;than initially estimated'''<br/><span class="author">Kochańczyk M</span>, <span class="author">Grabowski F</span>, <span class="author">Lipniacki T</span><br/>''Royal Society Open Science'' <u>7</u>:200786 (2020)<br/> [https://pubmed.ncbi.nlm.nih.gov/33047040 PubMed] [https://doi.org/10.1098/rsos.200786 CrossRef] | [https://royalsocietypublishing.org/doi/pdf/10.1098/rsos.200786 PDF] [https://royalsocietypublishing.org/doi/suppl/10.1098/rsos.200786 SuppInfo-PDF] [https://royalsocietypublishing.org/action/downloadSupplement?doi=10.1098/rsos.200786&file=rsos200786_review_history.pdf Correspondence]